A randomized, double-blind, double-dummy, active-and placebo-controlled, 5-way crossover study of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration

Trial Profile

A randomized, double-blind, double-dummy, active-and placebo-controlled, 5-way crossover study of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Oxycodone/naltrexone (Primary) ; Oxycodone
  • Indications Opioid abuse; Pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 Aug 2017 According to an Elite Pharmaceuticals media release, data from this study will be presented at PAINWeek 2017 National Conference.
    • 13 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top